lorlatinib
pfizer
['nsclc', 'sclc', 'lorlatinib']
a shp2 inhibitor as a booster for tki at the time of resistance? very interesting concept and innovative design for a phase i trial. one patient with alk+ nsclc heavily pretreated had a new response on lorlatinib combined with the shp2 inhibitor. to be confirmed. #asco23 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.